Method for producing Chinese hamster ovary cell strain, being a producer of recombinant SARS-CoV-2 virus protein RBD, Chinese hamster ovary cell strain, producer of recombinant SARS-CoV-2 protein RBD, method for producing recombinant SARS-CoV-2 virus protein RBD, test system for enzyme immunoassay of human serum or plasma, and use thereof

摘要

FIELD: biotechnology.;SUBSTANCE: The invention relates to the field of biotechnology. Created are a genetic construct for the expression of recombinant SARS-CoV-2 virus protein RBD, a strain of Chinese hamster ovary cells CHO-S-RBD that produces a recombinant protein - a receptor-binding domain (RBD) of SARS-CoV-2 virus, which can be used for diagnostic purposes. Described is a method for producing a strain of Chinese hamster ovary cells CHO-S-RBD being a producer of recombinant SARS-CoV-2 virus protein RBD, containing a genetic construct comprising SEQ ID NO: 1; introducing the specified genetic constructs into cells by lipofection; selecting cells on Hygromycin B antibiotic. Created is a strain of Chinese hamster ovary cells CHO-S-RBD, a producer of recombinant SARS-CoV-2 virus protein RBD. Developed is a method for producing recombinant SARS-CoV-2 virus protein RBD, comprising: culturing a strain of Chinese hamster ovary cells CHO-S-RBD; purifying chromatographically the recombinant SARS-CoV-2 virus protein RBD from culture medium of the Chinese hamster ovary strain CHO-S-RBD; confirming the production of recombinant SARS-CoV-2 protein RBD. Created is a recombinant SARS-CoV-2 virus protein RBD to detect antibodies to SARS-CoV-2. Created is a test system for enzyme immunoassay of human serum or plasma. Developed is a method for analyzing serum or plasma of COVID-19 convalescents to sample the most promising ones for treating patients infected with SARS-CoV-2. Developed is a method for analyzing human serum or plasma to determine the titer of antibodies to SARS-CoV-2 virus. The invention reduces time and simplifies the analysis of serum or plasma of COVID-19 convalescents to sample the most promising ones for treating SARS-CoV-2 infected patients. The invention also provides for high and stable expression of recombinant SARS-CoV-2 virus protein RBD.;EFFECT: invention provides a rapid and efficient test system for determining the most promising serum or plasma samples of COVID-19 convalescents for treating patients infected with SARS-CoV-2.;10 cl, 4 dwg, 6 tbl, 8 ex